

Policy	MM-036
Effective Date	09/01/2024
Reviewed/Revised Date	03/30/2026
Next Review Date	03/30/2027
Origination Date	07/01/2024
Originated Department	Clinical Operations

High Frequency Chest Wall Compression (e.g. The Vest Airway Clearance System)

Audience
Providers, Members, Brokers, MHC

Purpose
<p>Medical policies provide general support for applying Mountain Health Co-Op member policy document coverage decisions and must reference the member-specific benefit plan document. The terms of the member-specific Policy document may differ from the standard benefit plan on which this medical policy is based. If there is a conflict between a member-specific policy document and the Mountain Health Co-Op medical policy, the member-specific policy document supersedes this medical policy. Any person(s) applying this medical policy must identify member eligibility, the member-specific policy document, and related policies or guidelines before applying this medical policy, including the existence of any state or federal guidance. Mountain Health Co-Op medical policies are designed for informational purposes only and are not an authorization, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the member-specific policy document coverage. Mountain Health Co-Op reserves the sole discretionary right to modify all policies and guidelines at any time.</p>

Definition
<p>Respiratory disorders characterized by excessive respiratory secretions and impaired airway clearance include cystic fibrosis, chronic bronchitis, emphysema with a chronic bronchitic component, chronic asthma, dyskinetic cilia syndromes, diffuse panbronchiolitis, and idiopathic bronchiectasis. Neuromuscular diseases, such as muscular dystrophy, spinal muscular atrophy, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS) can also result in the inability of the patient to effectively clear mucus from the airways.</p>

When conventional postural drainage therapy and other devices have failed or are contraindicated, high-frequency chest wall compression (HFCWC) is often considered as a treatment option for patients with disease that cause difficulty clearing secretions. HFCWC, a mechanical form of chest physiotherapy, is a system composed of a fitted vest coupled to a pneumatic compressor that uses high frequency oscillation to provide chest physiotherapy. The compressor inflates and deflates the vest, compressing and releasing the chest wall to create airflow within the lungs. The vibrations, along with the increase in airflow, help loosen mucus from the lungs. Children as young as three years of age are able to use the vest.

HFCWC is an established airway clearance device for patients with cystic fibrosis who cannot tolerate chest physiotherapy or in whom chest physiotherapy has been shown to be ineffective or is contraindicated.

HFCWC (high-frequency chest wall compression devices) (e.g. the Vest™ Airway Clearance System, formerly known as the ABI Vest® or the ThAIRapy Bronchial Drainage System®) are passive oscillatory devices designed to provide airway clearance without the active participation of the patient. The Vest™ Airway Clearance System provides high-frequency chest compression using an inflatable vest and an air-pulse generator. Large-bore tubing connects the vest to the air-pulse generator. The air-pulse generator creates pressure pulses that cause the vest to inflate and deflate against the thorax, creating high-frequency chest wall oscillation and mobilization of pulmonary secretions.

Policy/Procedure

Commercial Plans/CHIP

Mountain Health Co-Op covers high frequency chest wall compression therapy in limited clinical circumstances.

1. Medical Necessity Criteria for Coverage HFCWC Therapy (Must Meets 1.1-1.4):

1.1 Member has one of the following conditions:

- a)** Cystic fibrosis;
- b)** Chronic diffuse bronchiectasis, which is defined by a daily productive cough for at least 6 continuous months, or more than 2 times a year exacerbations requiring antibiotic therapy, and confirmed by high resolution or spiral chest computed tomography scan;
- c)** Chronic neuromuscular disease with respiratory muscle weakness affecting the ability to cough or clear respiratory secretions with prior history of pneumonia or other significant worsening of pulmonary function;
- d)** Immotile Ciliary Dysfunction/Primary Ciliary Dyskinesia.

1.2 There is documentation of either failure of or inability to use other airway clearance therapies including manual chest physical therapy due to any one of the following:

- a)** There are 2 or more individuals with cystic fibrosis, chronic bronchiectasis, or chronic neuromuscular disorder (meeting criteria above) in the family
- b)** The caregiver is unable (physically or mentally) to perform chest physical therapy at the required frequency

- c) There is no available caregiver, parental or partner resource to perform chest physical therapy
- d) Well-documented failure of standard treatments to adequately mobilize retained secretions, with ALL the following (i-iii):
 - i. Failed Chest PT at least twice daily; and
 - ii. A pattern of hospitalizations or significantly deteriorating clinical condition; and
 - iii. Adequate cough to remove mobilized secretions or use of cough assist device.

1.3 There is documentation of an initial 60 day trial during which at least an 80% compliance with the device has been demonstrated AND the patient has documentation of improved ventilator function; and

1.4 The device is prescribed by a pulmonary specialist.

2. Mountain Health Co-Op considers continued use of a high frequency chest compression device is medically necessary when ongoing use, (that is, compliance with use) is documented at 6 month to 12 month intervals. (Note: For high frequency chest compression devices with usage meters, documentation should reflect use, in general, at least 80% of the prescribed time).

3. Mountain Health Co-Op considers high frequency chest compressions NOT medically necessary if the above criteria are not met.

4. Mountain Health Co-Op considers high chest wall frequency chest compression not medically necessary for all other indications, including but not limited to, chronic obstructive pulmonary disease (COPD), Cerebral Palsy and individuals with known cardiac conditions.

5. Clinical rationale

5.1 The evidence from 3 Cochrane systematic reviews (Morrison et al., 2014, McIlwaine et al., 2015 and Mckoy et al., 2016) also found a low level of evidence for the use of HFCWC in patients with CF. However, further studies are needed.

5.2 The evidence for use of these vests in neuromuscular disease is limited. The studies tend to be small without randomization. There are 2 studies, a 2016 retrospective review (Lechtzin et al.) and a 2022 prospective cost analysis (Ansaripour et al.), both of which suggest cost is less due to decreased hospitalization. The majority of clinics that deal with these patients feel that by the time HFCWC is initiated, randomized trials are no longer ethical due to the precarious nature of their disease.

5.3 A prospective, RCT of high-frequency chest wall oscillation (HFCWC) in 23 pediatric patients 14 with NMD and 9 cerebral palsy (CP) (Yuan et al., 2010). Twenty three patients (9 with CP and 14 with NMD) were randomized to receive either HFCWC or standard CPT. The mean study period was 5 months. Outcome measures included respiratory-related hospitalizations, antibiotic therapy, CXR and polysomnography. No significant changes were seen between the two groups for any of these outcome measures. Adherence to prescribed regimen was however higher with HFCWC ($p = 0.036$). The authors concluded that the data suggests safety, tolerability and improved compliance with HFCWC but acknowledged that larger, controlled trials are needed to confirm results. Study limitations include small sample size, which

could have resulted in not detecting clinically significant differences heterogeneous nature of diagnoses and short-term follow-up.

- 5.4** In 2014, a single-center, prospective study (Fitzgerald et al.) evaluated the clinical feasibility of HFCWC therapy in neurologically impaired children with respiratory symptoms. Twenty Two participants were studied for 12 months before and 12 months after initiation of HFCWC therapy, and 15 subjects were followed for an additional 12 months. The threshold of adherence to the therapy was 70%. The number of pulmonary exacerbations that required hospitalization was recorded, noting 45% of the subjects required hospital admission before initiation of HFCWC therapy. This rate decreased to 36% after the first year and to 13% after the second year with this therapy. There was a statistically significant reduction of the number of hospital days at follow-up compared to pre-treatment. Use of an assisted cough device or the presence of tracheostomy did not significantly affect hospitalization days. The authors found that regular HFCWC therapy may reduce the number of hospitalizations in neurologically impaired children. However, these findings are limited by lack of concurrent comparison group undergoing a different therapeutic approach.
- 5.5** A 2016 cohort study (Lechtzin et al.) analyzed healthcare claims before and after initiation of HFCWC to compare whether this modality led to improved respiratory outcomes as measured by lower healthcare use for patients who have a chronic neuromuscular disease (NMD). Data were obtained from 2 large databases of commercial insurance claims. Study subjects (n=426, pediatric and adult) were commercial insurance members with an International Classification of Diseases, Ninth Revision, code for a NMD and a claim for HFCWC between 2007 and 2011. To account for the possibilities of misclassification based on diagnoses and bias due to loss to follow-up, outcomes between those lost to follow-up and those who were not, and similar results were found. In conclusion, the total medical costs, hospitalizations, and pneumonia claims were less after initiation of HFCWC in a broad group of patients with NMD. Limitations of the study included administrative data that did not capture how HFCWC was used and that HFCWC may be a marker of generally better care in the routine use of this intervention in the care of patients with NMD. Also, findings are limited by lack of concurrent comparison group undergoing a different therapeutic approach.
- 5.6** In 2019 ECRI identified and reviewed 1 international single-blind RCT (n=73), 1 international open label RCT (n=50), and 1 prospective case series (n=25) conducted in the U.S. in a custom product brief on The Vest Airway Clearance System®. They stated that the available evidence is too limited in quantity and quality to permit conclusions on the product's safety and effectiveness for use in hospitalized patients with respiratory failure who do not have CF. While all reported short-term positive outcomes, patient prognoses and complication risks weren't directly comparable. The case series was at high risk of bias from lack of a control group. The two RCTs included appropriate control groups and treatment randomization but were at high risk of bias because of small sample size, single-center focus, and one study lacked blinding as to treatment group. Each study was conducted in a different country, and results may not generalize to other health systems. In conclusion, to better help providers in making informed decisions on

how well HFCWC with the Vest system works relative to other mechanical or intrapulmonary flow percussion devices, more robust, multicenter blinded RCTs are needed.

- 5.7** Lastly, in 2022 Anasaripour et al. investigated the budget impact of HFCWO versus chest wall physical therapy (CWPT) in patients with complex neuromuscular disorders (cNMD) from a U.S. commercial payer perspective. In combination with a previously developed cost-effectiveness model, a budget impact model was developed to evaluate the incremental budgetary impact associated with introducing a HFCWO device over a 5-year time horizon. In a hypothetical plan of 1,000,000 members (men: 49.2%), 2099 patients with cNMD were estimated to be eligible to receive airway clearance services over 5 years. The new scenario (HFCWO and CWPT [US\$24 PMPY]) was cost-saving compared with the current scenario (CWPT only [\$34 PMPY]) with a cost reduction of US\$9.46 PMPY. The model estimated a net cost-saving of US\$1,594,131 and US\$9,591,343 over 1 and 5 years, respectively. The authors found that this study suggests the HFCWO technique to manage the reduction in vital capacity in patients with cNMD would lead to favorable budget impact results.
- 5.8** American Academy of Neurology (AAN) (Miller et al., 2009; reaffirmed 2020) in their practice parameters on the care of patients with amyotrophic lateral sclerosis (ALS), concluded that high frequency chest wall compression (HFCWC) is unproven for adjunctive airway secretion management.
- 5.9** National Institute for Health and Clinical Excellence (NICE): In a guidance for the management of cystic fibrosis, NICE (2017, updated 2022) stated that HFCWC should not be offered as an airway clearance technique for people with cystic fibrosis except in exceptional clinical circumstances because the evidence has shown that high-frequency chest wall oscillation is not as effective as other airway clearance techniques. Airway clearance techniques for these patients should be individualized based on the patients' ability to clear mucus from their lungs, and all factors that may influence adherence should be considered. The effectiveness of the technique should be assessed frequently and modified as needed.
- 5.10** In a consensus statement on the respiratory care of patients with Duchenne muscular dystrophy (DMD), the American Thoracic Society (ATS) states that effective airway clearance is critical for patients with DMD to prevent atelectasis and pneumonia. Ineffective airway clearance can hasten the onset of respiratory failure and death, whereas early intervention to improve airway clearance can prevent hospitalization and reduce the incidence of pneumonia. HFCWC has been used in patients with neuromuscular weakness but there are no published data on which to base a recommendation. Any airway clearance device predicated upon normal cough is less likely to be effective in patients with DMD without concurrent use of assisted cough. Patients with DMD should be taught strategies to improve airway clearance and how to employ those techniques early and aggressively. ATS recommended use assisted cough technologies in patients whose clinical history suggests difficulty in airway clearance, or whose peak cough flow is less than 270 L/minute and/or whose maximal expiratory pressures are less than 60

cm H2O. Data is extremely limited for disorders such as COPD and does not support the use of this vest with these types of disorders.

Applicable Coding

CPT Codes

No applicable CPT codes

HCPCS Codes

- A7025** High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment, each
- A7026** High frequency chest wall oscillation system hose, replacement for use with patient-owned equipment, each
- E0483** High frequency chest wall oscillation system, with full anterior and/or posterior thoracic region receiving simultaneous external oscillation, includes all accessories and supplies, each

ICD-10 Codes:

- A15.0** Tuberculosis of lung (tuberculous bronchiectasis)
- E84.0-E84.9** Cystic Fibrosis
- G12.0-G12.9** Spinal muscular atrophy and related syndromes
- G24.9** Dystonia, unspecified
- G35** Multiple sclerosis
- G71.2** Congenital myopathies
- G71.11-G71.19** Myotonic disorders
- G72.0-G72.9** Other and unspecified myopathies
- J47.0-J47.9** Bronchiectasis
- G82.20-G82.54** Paraplegia (paraparesis) and quadriplegia (quadriparesis) [regardless of underlying etiology]
- J98.09** Other diseases of bronchus, not elsewhere classified
- J98.6** Disorders of diaphragm (paralysis of the diaphragm)
- Q33.4** Congenital bronchiectasis
- Q34.8** Other specified congenital malformations of respiratory system
- Q89.3** Situs inversus

Vendors

- **Personify**
- **HPS**

References

1. American Academy of Neurology (AAN). Practice parameter update: The care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies Oct 2009; Updated Apr 2017, January 11, 2020. Accessed: January 5, 2023. Available at URL address: <https://www.aan.com/Guidelines/home/GuidelineDetail/370>
2. Ansari-pour, A., et al. (2022). "Budget Impact of the Vest High Frequency Chest Wall Oscillation System for Managing Airway Clearance in Patients with Complex Neurological Disorders" *Pharmacoecon Open* 6(2): 169-178. PMID: PMC8864050

3. ECRI (Emergency Care Research Institute). Custom Product Briefs. The Vest Airway Clearance System® (Hill-Rom, Inc.) for clearing lung and airway secretions in hospitalized patients without Cystic Fibrosis. June 2019.
4. El Haddad L, Khan M, Soufny R, Mummy D, Driehuys B, Mansour W, Kishnani PS, ElMallah MK. Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives. *Ther Clin Risk Manag.* 2023 Sep 1;19:713-729. doi: 10.2147/TCRM.S362871. PMID: 37680303; PMCID: PMC10480292.
5. Finder JD, Birnkrant D, Carl J, et al. American Thoracic Society. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. *Am J Respir Crit Care Med.* 2004 Aug 15;170(4):456-65.
6. Fitzgerald K, Dugre J, Pagala S, et al. High-frequency chest wall compression therapy in neurologically impaired children. *Respir Care.* 2014 Jan;59(1):107-12.
7. Goyal, V., MBBS, DCH, FRACP, PhD. Chang, A., MBBS, FRACP, PhD, FAPSR, FAHMS. UpToDate®. "Management of Bronchiectasis in Children without Cystic Fibrosis". Literature current through: April 2022. Topic last updated: September 21, 2021. Accessed: January 5, 2023. Available at: <https://www.uptodate.com/contents/management-of-bronchiectasis-in-children-without-cystic-fibrosis>
8. Lechtzin N, Wolfe LF, Frick KD. The impact of high-frequency chest wall oscillation on healthcare use in patients with neuromuscular diseases. *Ann Am Thorac Soc.* 2016 Jun;13(6):904-9.
9. Main E, Rand S. Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. *Cochrane Database Syst Rev.* 2023 May 5;5(5):CD002011. doi: 10.1002/14651858.CD002011.pub3. PMID: 37144842; PMCID: PMC10161870.
10. McIlwaine M, Button B, Dwan K. Positive expiratory pressure physiotherapy for airway clearance in people with cystic fibrosis. *Cochrane Database Syst Rev.* 2015;6:CD003147
11. Mckoy NA, Wilson LM, Saldanha JJ, Odelola OA, Robinson KA. Active cycle of breathing technique for cystic fibrosis. *Cochrane Database Syst Rev.* 2016;7:CD007862
12. McShane PJ. Investigation and Management of Bronchiectasis in Nontuberculous Mycobacterial Pulmonary Disease. *Clin Chest Med.* 2023 Dec;44(4):731-742. doi: 10.1016/j.ccm.2023.07.005. PMID: 37890912.
13. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. *Neurology.* 2009 Oct 13;73(15):1227- 33.
14. Morrison L, Agnew J. Oscillating devices for airway clearance in people with cystic fibrosis. *The Cochrane Database Systematic Rev.* 2014;7:CD006842
15. Morrissey BM, Harper RW. Bronchiectasis: sex and gender considerations. *Clin Chest Med.* 2004 Jun;25(2).
16. National Institute for Health and Care Excellence (NICE). Cystic fibrosis: diagnosis and management guideline [NG78]. Oct 2017. Accessed: January 5, 2023.. Available at URL address: <https://www.nice.org.uk/guidance/ng78>
17. National Institute for Health and Care Excellence (NICE). The Vest for delivering high-frequency chest wall oscillation in people with complex neurological needs. Medtech innovation briefing [MIB159] Published date: September 2018.
18. National Institute for Health and Clinical Excellence (NICE). Chronic obstructive pulmonary disease in over 16s: diagnosis and management [NG115]. Dec 2018. Updated Jul 2019. Accessed January 5, 2023. Available at URL address: <https://www.nice.org.uk/guidance/NG115>
19. Patel N, Howard IM, Baydur A. Respiratory considerations in patients with neuromuscular disorders. *Muscle Nerve.* 2023 Aug;68(2):122-141. doi: 10.1002/mus.27845. Epub 2023 May 29. PMID: 37248745.
20. Yuan N, Kane P, Shelton K, et al. Safety, tolerability, and efficacy of high-frequency chest wall oscillation in pediatric patients with cerebral palsy and neuromuscular diseases: an exploratory randomized controlled trial. *J Child Neurol.* 2010 Jul;25(7):815-21.

Review/Revision/Approval History	
Date	Description
07/01/2024	New Policy
03/30/2026	Reviewed and approved by Mountain Health CO-OP Policy Committee

Disclaimer
<p>This document is for informational purposes only and should not be relied on in the diagnosis and care of individual patients. Medical and Coding/Reimbursement policies do not constitute medical advice, plan preauthorization, certification, an explanation of benefits, or a contract. Members should consult appropriate healthcare providers for medical advice, care, and treatment. Benefits and eligibility are determined before medical guidelines and payment guidelines are applied. Benefits are determined by the member’s benefit plan, effective when services are rendered.</p> <p>The codes for treatments and procedures applicable to this policy are included for informational purposes. Including or excluding a procedure, diagnosis, or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as they apply to an individual member.</p> <p>Mountain Health Co-Op makes no representations and accepts no liability regarding the content of any external information cited or relied upon in this policy. Mountain Health Co-Op updates its Coverage Policies regularly and reserves the right to amend these policies and give notice per State and Federal requirements. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Mountain Health Co-Op.</p> <p>”Mountain Health Co-Op” and its accompanying logo and marks are protected and registered trademarks of Mountain Health Co-Op. The content of this Service is proprietary and protected by copyright. You may access the copyrighted content of this Service only for purposes outlined in these Conditions of Use.</p> <p>© CPT Only – American Medical Association</p>